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Agonistic αCD40 Ab’s have been shown to be potent immune adjuvants for both cell- and humoralmediated immunity. While enhancing short-lived humoral immunity, the administration of a CD40
agonist during thymus-dependent immune responses ablates germinal center formation, prematurely
terminates the humoral immune response, blocks the generation of B cell memory, and prevents the
generation of long-lived bone marrow plasma cells. Interestingly, some of these effects of heightened
CD40 engagement could be mimicked by enhancing the magnitude of antigen-specific T cell help.
Taken together, these studies demonstrate that as the magnitude of CD40 signaling intensifies, the
fate of antigen-reactive B cells can be dramatically altered. These are the first studies to describe the
multifaceted function of CD40 in determining the fate of antigen-reactive B cells and provide novel
insights into how CD40 agonists can short-circuit humoral immunity.
J. Clin. Invest. 109:613–620 (2002). DOI:10.1172/JCI200214110.

Introduction
Interrupting CD154-CD40 interactions prevents the
development of thymus-dependent (TD) humoral
responses and many cell-mediated immune responses
(1). Conversely, it has been shown that agonistic
αCD40 Ab’s administered in vivo can act as potent
immune adjuvants for both arms of the immune
response. Several reports have shown that αCD40
enhances the immune response to thymus-independent (TI) antigens (2, 3) and can amplify cell-mediated
immune responses to viruses and tumors (4–6). Given
these observations, the clinical use of CD40 agonists to
boost the immune response of the immunocompromised host has been considered.
We have investigated whether CD40 agonists can
influence the follicular versus extrafollicular differentiation of antigen-experienced B cells. Antigen-specific B
cells that are activated by CD154-dependent cognate
interactions with T cells traffic either to follicles or to
extrafollicular foci. Follicular B cells in the spleen that
are recruited to form germinal centers (GCs) ultimately
differentiate to memory B cells and/or to long-lived plasma cells that migrate to the bone marrow where they
sustain high-affinity, antigen-specific Ig levels in the
serum (7–11). In contrast, B cells that emigrate to
extrafollicular foci within the red pulp, following interactions with T cells, locally differentiate to short-lived
Ab-secreting cells (ASCs) that produce low-affinity Ig
(12–14). Here, we document that the administration of
The Journal of Clinical Investigation

|

a CD40 agonist (αCD40 mAb), in combination with a
TD antigen, ablates GC formation and induces a pattern
of extrafollicular B cell differentiation in the spleen and
lymph node. This CD40-induced deviation resulted in a
heightened early humoral immune response, the premature termination of the humoral immunity, loss of
long-lived bone marrow plasma cells, and memory B cell
development. Interestingly, priming of the T cell compartment to enhance CD40 signaling mimicked some
but not all of the effects of the αCD40 agonist. This latter data indicates that extrafollicular B cell differentiation by heightened CD40 signaling may represent a
physiological means to limit the duration and intensity
of the humoral immune response. Taken together, these
studies demonstrate that αCD40, as well as the magnitude of helper T cell activity, can influence the follicular/extrafollicular fate of antigen-reactive B cells.

Methods
Mice. C57/BL6 Ly5.2 congenic mice and CD40–/–
C57/BL6 mice, 6–8 weeks old, were bred and maintained in the specific pathogen-free animal facility at
Dartmouth Medical School, Lebanon, New Hampshire,
USA. QM mice were backbred to the C57/BL6 JH–/– Jk–/–
strain for nine generations to produce QM F9 C57/BL6
mice. IghCD40 mice were generated as described previously (15). Briefly, wild-type human CD40 cDNA was
cloned into the pEmVhp expression vector containing
the mouse rearranged H chain promoter derived from
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pMO-µ4C8 and microinjected into C57/BL6 oocytes.
Mice were backcrossed to murine CD40–/– mice of a
C57/BL6 background, thereby allowing the expression
of human CD40 exclusively in the B cell compartment.
B cell preparation and adoptive transfer. Spleen cell suspensions isolated from QM mice were treated with
ammonium chloride-Tris buffer and were T cell depleted using anti–Thy-1.2 plus anti-CD4 Ab and rabbit
complement (Accurate Chemical & Scientific Corp.,
Westbury, New York, USA). An aliquot of cells was
stained with the R2348.8 4-hydroxy-5-nitrophenylacetyl
(NP) idiotype-specific mAb and the pan B cell marker,
B220, and analyzed by flow cytometry (FACScan; Becton Dickinson Immunocytometry Systems, San Diego,
California, USA) to determine percentage of Tg B cells.
In all experiments, normal rat serum was added to minimize nonspecific staining. Tg B cells (3 × 106) were
adoptively transferred intravenously into sex-matched
C57/BL6 Ly5.2 recipient mice. All experiments consisted of three mice per group.
Immunization and αCD40 treatment. NP30-KLH and NPFicoll were purchased from Solid Phase Sciences Inc.
(San Rafael, California, USA). To examine TD responses, recipient mice were challenged intraperitoneally 24
hours after adoptive transfer with CFA alone or with
100 µg NP-KLH emulsified in CFA in the absence or
presence of FGK115. FGK115, an agonistic rat IgG2a
anti-mouse CD40, was HPLC-purified and administered at 100 µg intraperitoneally on day 0, 2, and 4 after
immunization. As indicated, control rat IgG was administered similarly to FGK115. In some experiments, mice
were immunized intraperitoneally with 200 µl of a 10%
solution of sheep blood alsevers (Colorado Serum Co.,
Denver, Colorado, USA) and treated with S2C6 (16), an
agonistic anti-human CD40 mAb. Mice were killed on
day 7, and intact spleens were removed and sera collected by retro-orbital eye bleeds. For experiments using carrier-primed T cells, recipient mice were challenged
intraperitoneally with 100 µg KLH emulsified in CFA 1
week prior to cell transfer. Recipients were immunized
intraperitoneally and subcutaneously with 100 µg NPKLH precipitated in alum, and analyses were performed
on day 5 after immunization. Secondary immune
responses were assessed by pooling T cell–depleted
splenic B cells from primary recipients 30 days after
immunization and by transferring 10 × 106 cells intravenously into secondary recipients that were KLHprimed 2 weeks previously. Hosts were challenged with
alum alone or with 100 µg NP-KLH alum 24 hours after
transfer, and serum was collected 7 days later. Endogenous levels of high-affinity anti-NP IgG1 and IgG2a were
detected by ELISA. Long-lived bone marrow ASCs generated from the spleen or lymph node were quantified
by ELISPOT 7 days after transferring normalized numbers of Tg B cells into naive secondary hosts.
Flow cytometric reagents. The following mAbs were used
for multicolor flow-cytometric analysis: 6B2, a rat
IgG2a; anti-mouse B220, a rat IgM anti-mouse GL7; and
CD45.2, a rat IgG2a anti-mouse Ly5.1 and Ly5.2, were
614
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purchased from PharMingen (San Diego, California,
USA). FITC-conjugated Ab90, a rat IgG2a anti-mouse
CD38, and FITC-conjugated peanut agglutinin (PNA)
were purchased from Sigma Chemical Co. (St. Louis,
Missouri, USA). The anti-VH17.2.25 cell line (R2348.8)
was generously provided by Theresa Imanishi-Kari
(University of California San Francisco, San Francisco,
California, USA). Streptavidin-phycoerythrin (streptavidin-PE) and FITC were obtained from Southern
Biotechnologies Associates (Birmingham, Alabama,
USA). For removal of cytophilic Ig, cells were washed in
5% FCS in BSS and resuspended in low-pH (pH 4.0)
acetate buffer containing 0.05 M Na acetate, 0.085 M
NaCl, and 0.005 M KCl and 2% FCS in distilled H2O.
Samples were incubated on ice for 1 minute followed
by the addition of an equal volume of 0.1 M Tris buffer,
pH 8.0, containing 2% FCS. Samples were washed twice
in 5% FCS BSS and then stained. Chromatographically purified rat IgG was used as isotype control. A minimum of 200,000 events per sample were collected on a
FACScan, and dead cells were excluded based on forward and 90° light scatter.
ELISA and ELISPOT reagents. NP-25–BSA or NP-4–BSA
was used to capture NP-specific Ab’s in a sandwichbased ELISA. Allotypic-specific (Igha or Ighb) goat antimouse IgG1 and IgG2a conjugated to alkaline phosphatase (Southern Biotechnology Associates) were used
to detect Ab derived from Tg or endogenous B cells with
subsequent development with phosphatase substrate
(Sigma Chemical Co.). Absorbance was read at a dual
wavelength of 405 and 540 nm using an MR700 plate
reader (Dynatech Laboratories, Chantilly, Virginia,
USA). Serum from a hyperimmunized QM mouse was
used as a standard in all assays to determine nanograms
per milliliter. For ELISPOT analysis, a modified manufacturer’s protocol was used from Millipore Corp. (Beverly, Massachusetts, USA). Briefly, Millipore MultiScreen HA plates were coated with either NP-25–BSA or
NP-4–BSA. Normalized numbers of Tg B cells were plated in triplicate at a starting concentration of 2.4 × 106
cells, serially titrated, and incubated at 37°C for 5 hours.
Tg ASCs were detected with allotype-specific (Igha)
biotin-conjugated rat anti-mouse IgG1a followed by
development with streptavidin–horse radish peroxidase
and chromogen substrate, and counted.
Confocal image analysis. On day 5 or 7 after immunization, intact spleens and lymph nodes were harvested
and 4- to 5-µm frozen sections were fixed in acetone at
4°C for 15 minutes and allowed to air dry at 4°C for 48
hours prior to staining. Sections were stained in 1%
BSA PBS using a three-color protocol with rat antimouse Ab’s: 6B2 FITC, CD4-, and CD8-PE, and Cy5conjugated anti-NP idiotype VH17.2.25. To block nonspecific binding, 1% mouse serum and 10% normal rat
serum were included in the staining process. Samples
were analyzed on a Bio-Rad 1024 confocal microscope
(Bio-Rad Laboratories Inc., Hercules, California, USA).
RT-PCR. On day 7 after immunization, T cell–depleted splenocytes were dual stained with biotin-conjugatMarch 2002
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ed anti-NP idiotype VH17.2.25 and Ly5.1 to label Tg B
cells. Tg B cells were positively selected (≥ 90% purity)
using streptavidin-coupled microbeads (Miltenyi
Biotec, Auburn, California, USA). Total RNA (1 µg each)
isolated from purified Tg B cells by using RNeasy system (QIAGEN Inc., Valencia, California, USA) was used
as a template for cDNA synthesis with Superscript II
System (Life Technologies Inc., Rockville, Maryland,
USA). PCR amplification was carried out by titrating
cDNA samples with Taq (Boehringer Mannheim
GmbH, Mannheim, Germany) and the primers for
HPRT to normalize levels of template. Amplification of
BSAP and Blimp-1 transcripts were carried out using normalized amounts of cDNA. The primers used were as
follows: 5′-GCTGGTGAAAAGGACCTCT-3′ (HPRT forward) and 5′-CACAGGACTAGAACACCTGC-3′ (HPRT
reverse); 5′-TCCTCGGACCATCAGGACAG-3′ (BSAP forward) and 5′-CCTGTTGATGGAGCTGACGC-3′ (BSAP
reverse); 5′-TCCGGCTCCGTGAAGTTTCAA-3′ (Blimp-1 forward) and 5′-GGTGGAACTCCTCTCTGGAAT-3′ (Blimp-1
reverse). Conditions used for amplification were 94°C,
55°C/65°C, and 72°C for 35 cycles. HPRT was used as
a control to confirm the amount of each template.

Results
Anti-(α)CD40 administration aborts GC B cell differentiation. We have developed a system using Tg B cells that
faithfully recapitulates the humoral immune response
to TD antigens and provides the means to track clonal

B cell behavior in vivo. Tg B cells can be clearly identified by virtue of their antigen specificity to NP, the
expression of the VH17.2.25 idiotype, and by the expression of the allotypic marker, Ly5.1, when using congenic Ly5.2 mice as recipients. Tg B cells vigorously
expand by day 7 after challenge with the TD antigen,
NP-KLH (2). To evaluate how CD40 agonists alter clonal expansion and differentiation of B cells during TD
responses, recipients were immunized in the presence
or absence of agonistic αCD40 mAb. Total numbers of
Tg B cells present in the spleens of immune mice were
quantified at day 7 after immunization. Immune Tg B
cells expanded approximately threefold over naive control animals, regardless of control Ig or αCD40 treatment (Figure 1a). As demonstrated here and reported
previously (2), Tg B cells failed to undergo expansion in
recipients that were administered αCD40 in the
absence of antigen. These results indicate that Tg B cell
expansion is antigen-driven and that increasing CD40
engagement by the addition of αCD40 mAb does not
enhance the proliferative phase of Tg B cell activation.
A hallmark of follicular B cell differentiation is the
generation of GCs. GC formation and kinetics in this Tg
system can be readily quantified by flow cytometric
analysis of the Tg B cells using a panel of GC-specific
markers (17–19). Tg B cells from the spleens of immune
recipients exhibited a GC phenotype as demonstrated
by the upregulation of PNA and GL7 staining and the
downregulation of CD38 expression (Figure 1b). In con-

Figure 1
αCD40 treatment aborts a GC phenotype and promotes extrafollicular localization of Tg B cells. (a) Total numbers of splenic Tg B cells (antiNP idiotype+, B220+) were measured on day 7 after immunization. (b) Spleen or LN cells from naive (black line), immune/RIgG (red line),
and immune/αCD40 (blue line) were stained with GC markers. Histograms shown represent the relative intensity of the indicated marker
on Tg B cells (B220+ Id+). (c) Spleen cells from naive and immune IghCD40 transgenic mice treated with rat IgG or agonistic αhCD40 mAb
were stained with GC markers. The percentage of total PNA+ GL7+ GC B cells are indicated in each panel. (d) Frozen sections from intact
spleens were costained with B220 (green), CD4, and CD8 (red), and anti–NP idiotype (Id) 17.2.25 (blue) Ab’s, and analyzed by confocal
microscopy. Objective: ×20; zoom 1.5. Data are representative of three independent experiments.
The Journal of Clinical Investigation
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Figure 2
Administration of αCD40 reduces the duration of humoral immune
responses. Serum αNP IgG1a levels were measured by ELISA on days
indicated after immunization. Values are a composite of three mice
per group. Data are representative of three experiments.

trast, Tg B cells from immune recipients treated with
αCD40 lacked all three markers of GC phenotype, yet
expanded similar to mice challenged with antigen alone.
Tg B cells isolated from lymph nodes (LNs) of immune
recipients expanded, and, as observed in the spleen,
treatment with αCD40 prevented the emergence of a
GC phenotype (Figure 1b). Extensive analysis of Tg B
cells at time points earlier or later (from days 2–9) than
day 7 (from LNs or spleen) demonstrated that αCD40
administration universally prevented the appearance of
a GC phenotype. Hence, the failure of immune Tg B
cells to acquire a GC phenotype with αCD40 treatment
was not due to a delay or an early onset in the kinetics
of GC formation (data not shown).
To determine whether the loss in GC phenotype with
αCD40 treatment was a direct effect on Tg B cells, adoptive transfer experiments were carried out in CD40–/–
recipients. Similar to findings in wild-type recipients, Tg
B cells in immune CD40–/– recipients showed a threefold expansion over naive controls, regardless of αCD40
administration (Figure 1a). Results also showed that
αCD40 administration prevents the acquisition of a GC
phenotype on immune Tg B cells in CD40–/– mice (Figure 1b). These findings strongly suggest that αCD40
administration is exerting its effect directly on Tg B cells
and not via an indirect effect on other CD40-bearing
accessory cells. Thus, CD40 signaling provided by
endogenous helper T cells induced expansion and follicular B cell differentiation in immune recipients, and
αCD40 treatment significantly diverted the capacity of
these cells to acquire a GC phenotype and enter the follicular differentiation pathway.
In an effort to further confirm the in vivo effects of
αCD40 treatment on B cell differentiation, we performed similar experiments using transgenic mice
(IghCD40) that express human CD40 exclusively in the
B cell compartment. IghCD40 mice were immunized
with sheep red blood cells in the presence or absence of
the agonistic anti-human CD40 mAb, S2C6 (16). B cells
from the spleens of immune mice exhibited a GC phenotype as shown by PNA and GL7 expression (Figure
1c). In contrast, immune mice treated with S2C6 prevented the acquisition of GC B cells. These findings
616
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indicate that the differential effect of exaggerated CD40
signaling on B cell responses is not unique to a particular TD antigen or agonistic αCD40 mAb. Moreover,
these results provide additional evidence that αCD40
treatment acts directly on antigen-activated B cells.
We examined the histology of spleen sections from
recipient mice to determine the anatomical localization
of Tg B cells. On day 7 after immunization (peak expansion), tissue sections taken from intact spleens of naive
or immune mice without or treated with αCD40 were
stained with B220, CD4, and CD8, and anti-NP idiotype VH17.2.25 to delineate Tg B cells within the B and
T cell areas. Results showed that immunization with a
TD antigen, in the absence of αCD40, induced the
appearance of several clusters of immune Tg B cells
(B220+ Id+) located at the interface between the T
cell–rich zone of the periarteriolar lymphoid sheath
and the surrounding follicular B cells (Figure 1d). In
contrast, Tg B cells from immune recipients treated
with αCD40 were found exclusively in the extrafollicular space of the red pulp. These findings are consistent
with the lack of GC phenotype and demonstrate that
when CD40 engagement is heightened during TD
responses, antigen-reactive B cells are diverted to the
extrafollicular areas in the spleen.
CD40 agonists reduce the duration of humoral immune
responses and ablate the generation of B cell memory. The dramatic alterations in follicular B cell differentiation
induced by CD40 agonists would predict that CD40
agonists should alter the intensity or duration of the
overall humoral immune response. Hence, the magnitude and longevity of the serum IgG1a anti-NP (derived
from Tg B cells) was measured over a 3-week interval
when αCD40 was or was not administered. αCD40
treatment of immune recipients facilitated an earlier
onset of NP-specific IgG1a production and showed
twofold greater amounts of IgG1a anti-NP over mice
challenged with NP-KLH alone at day 7 after immunization (Figure 2). Furthermore, αCD40 treatment
altered the kinetics of IgG1a anti-NP responses by causTable 1
αCD40 treatment ablates secondary immune responses
Primary
recipients

Secondary
recipients

Naive
Naive
Immune
Immune
Naive + αCD40
Naive + αCD40
Immune + αCD40
Immune + αCD40

naive
immune
naive
immune
naive
immune
naive
immune

NP-4 binding
IgG1A

IgG2a

n.d.B
n.d.
0.26 ± 0.22
9.64 ± 2.7
n.d.
n.d.
n.d.
0.25 ± 0.14

n.d.
n.d.
n.d.
32.4 ± 3.0
n.d.
n.d.
n.d.
0.41 ± 0.01

Primary recipient mice were immunized with CFA (naive) or 100 µg NP-KLH
CFA (immune) in the absence or presence of αCD40. After 30 days, splenic B
cells from each group were adoptively transferred into carrier-primed secondary recipients and challenged with alum (naive) or 100 µg NP-KLH alum
(immune). Titers of high-affinity serum IgG levels were measured by ELISA on
day 7 after immunization. Data are representative of three experiments.
Aµg/ml. BNot detected (<2.0 ng/ml).
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Figure 3
αCD40 administration prevents the generation of bone marrow ASCs. Cells from spleen and bone marrow were isolated from the indicated recipients on day 7 (a) and day 21 (b) after immunization and assayed for total NP-specific IgG1a or high-affinity NP-specific IgG1a (c) by
ELISPOT using normalized numbers of Tg B cells. Results shown are representative of three independent experiments.

ing the premature termination of responses by 10 days
after immunization. Thus, αCD40 administration modestly enhanced early humoral immune responses but terminated the humoral immune response prematurely.
Since it appeared that αCD40 aborted GC formation
and prematurely terminated humoral immunity, we
assessed whether αCD40 could prevent the generation
of NP-specific memory B cells using normal, non-Tg B
cells. Mice were immunized with NP-KLH and administered αCD40 or control rat Ig. After 30 days, B cells were
isolated, transferred to secondary recipients, and challenged with antigen. Mice that received immune splenic
B cells produced significant titers of high-affinity NPspecific IgG1b and IgG2ab upon antigenic challenge
(Table 1). In contrast, secondary hosts that were given B
cells from mice that were immunized and administered
αCD40 failed to generate a memory response when
rechallenged with antigen. Thus, αCD40 administration
prevents the generation of memory B cells.
αCD40 agonists prevent the generation of long-lived plasma
cells in the bone marrow. Previous reports have shown that
a significant proportion of splenic Ab-secreting cells
(ASCs) that develop from extrafollicular differentiation
have a lifespan of less than 3 days (13, 20), thus providing local short-term Ab production. Study of the generation of long-lived plasma cells has revealed that many
of these are likewise derived in the spleen, but unlike
short-lived ASCs, long-lived plasma cells develop from
the follicular pathway and migrate to the bone marrow
where they can persist for months (10, 21). Because
αCD40 treatment terminates humoral immunity prematurely, we anticipated an impact of αCD40 treatment
on the generation of long-lived plasma cells. To examine
the production of short- and long-lived ASCs in our
studies, we performed ELISPOT analyses of spleen and
bone marrow in immune mice treated with αCD40.
Results from these studies demonstrated that Tg IgG1a
ASCs were present in the spleen of all immune recipients
7 days after challenge (Figure 3a). Analysis of splenic
ASCs generated by day 21 demonstrated a reduction in
Tg IgG1a ASCs in all recipients compared with day 7 and
illustrated the short-lived nature of most of the splenic
ASCs identified (Figure 3b). High numbers of long-lived
The Journal of Clinical Investigation
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IgG1a ASCs were apparent in the bone marrow of
immune mice and the majority of these underwent affinity maturation to produce high-affinity (NP-4–binding)
Ab (Figure 3c). The administration of αCD40 caused a
complete ablation of long-lived bone marrow Tg plasma
cells on all days tested. These results show that the terminal differentiation of follicular B cells to long-lived
plasma cells is ablated when CD40 signaling is elevated
during TD immune responses and explains the shortlived nature of the humoral immune response.
CD40 agonists alter the patterns of Blimp-1 and BSAP expression. The fact that αCD40 caused a marked diversion in B
cell differentiation led us to investigate if alterations in
differentiation-specific transcription factor expression
could be observed. BSAP (B lymphocyte–specific activation protein) and Blimp-1 (B lymphocyte–induced maturation protein 1) are transcriptional factors that have
been shown to be expressed during distinct phases of B
cell differentiation. BSAP is expressed on all differentiating B cells, except for cells that have terminally differentiated into short-lived ASCs or plasma cells residing in the
bone marrow (22). In contrast, Blimp-1 gene expression is
rapidly upregulated in B cells that have terminally differentiated to ASCs and plasma cells (23, 24). We examined

Figure 4
Administration of αCD40 upregulates Blimp-1 gene expression in
Tg B cells. PCR amplification of the indicated transcript was performed using normalized amounts of cDNA isolated from purified
splenic Tg B cells of recipients challenged with NP-Ficoll (TI
immune), NP-KLH (TD immune), or NP-KLH and treated with
αCD40 (TD immune + αCD40). Data are representative of three
mice per group from two independent experiments.
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Figure 5
Carrier-primed T cells prevent the acquisition of a GC phenotype in the spleen
but not in the LN and differentially control the generation of long-lived Tg ASCs.
(a) Total numbers of LN and splenic Tg B
cells were quantified 5 days after challenge. (b) Tg cells from naive (shaded
area) and immune (open area) recipients
were stained for the expression of the
indicated GC marker. Histograms shown
represent the relative intensity on gated
Tg cells isolated from LN and spleen.
Data are representative of six experiments. (c) Frozen sections from intact
spleen and LN were costained with B220
(green), CD4 and CD8 (red), and
anti–NP Id 17.2.25 (blue) Ab’s, followed
by confocal image analysis. Objective:
×20; zoom: 1.75. (d) Equivalent numbers
of naive and immune Tg B cells isolated
from spleen and LN of carrier-primed
recipients were transferred into secondary recipients that received neither priming nor antigen. Total numbers of bone
marrow NP-specific IgG1a ASCs were
quantified by ELISPOT analysis 7 days
after transfer. Data shown are representative of three independent experiments.

whether these transcriptional factors were regulated in
vivo by CD40 agonists during TD immune responses. Tg
B cells from recipients were purified on day 7 to 90% or
more by magnetic bead selection using the congenic
marker Ly5.1, and mRNA levels of BSAP and Blimp-1 were
evaluated. Adequate numbers of Tg B cells could be isolated only at the peak of expansion (day 7) and limited
the extent of the analysis. RT-PCR analysis demonstrated that BSAP mRNA was expressed at high levels in Tg B
cells isolated from recipients that were challenged with
NP-KLH compared with naive Tg cells (Figure 4). In contrast, Blimp-1 mRNA expression was present at low levels
in immune Tg cells. The differential expression of these
transcription factors support the notion that during TD
responses, Tg B cells are actively undergoing follicular differentiation. The low levels of Blimp-1 expression from
these follicular B cells is not surprising since terminal differentiation of long-lived plasma cell precursors occurs in
the bone marrow. Significantly, BSAP mRNA expression
was very low in immune Tg B cells that had been purified
from recipients treated with αCD40, but high levels of
Blimp-1 gene expression were observed. As an additional
control, Tg B cells were also purified from recipients that
were challenged with the TI antigen, NP-Ficoll, and tested for mRNA expression levels of BSAP and Blimp-1. B
cells that respond to TI antigens do not require cognate
interactions with helper T cells for activation and therefore culminate in the early activation and local differentiation of B cells to short-lived ASCs (25). Both BSAP and
Blimp-1 expression levels were elevated in TI-immune Tg
618
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B cells, as expected. These data demonstrate that elevated levels of CD40 signaling diverts B cells along the
extrafollicular differentiation pathway and differentiates
locally into short-lived ASCs.
Enhanced T cell help mimics some, but not all, of the effects of
CD40 agonists on follicular B cell differentiation. The above
findings suggest that enhanced CD40 engagement by
αCD40 administration directs antigen-reactive B cells
to the extrafollicular differentiation pathway. While this
provides valuable insights into how CD40 agonists may
alter the humoral immune response, does enhanced
CD40 engagement by helper T cells (Th cells) exert similar immunological effects on B cell differentiation? The
magnitude of CD40 signaling of B cells by Th cells
could be enhanced by the increased frequency of Th
cells and density of CD154 on memory Th cells. Priming the T cell compartment with antigen in CFA would
both increase the frequency of carrier-reactive Th cells
and produce a population of memory Th cells that have
higher densities of CD154 (26).
We tested whether T cell priming causes alterations
in B cell differentiation by using recipient mice that
were hyperimmunized with the carrier, KLH, in CFA.
Following the transfer of Tg B cells into the carrierprimed recipients, they were challenged (intraperitoneally and subcutaneously) with alum alone or NPKLH precipitated in alum. This systemic and regional
immunization assured T cell priming both in the
spleen and LN. In mice that were carrier-primed,
immune Tg B cells in both LN and spleen expanded
March 2002
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approximately tenfold over naive controls (Figure 5a).
These levels of B cell expansion were consistently higher than those observed in recipients that were not KLHprimed (Figure 1a) and demonstrated that carrierprimed T cells provided superior helper activity to naive
T cells and that they were present in the spleen and LN.
The differentiation of Tg B cells in the LN and spleen
from naive and carrier-primed immune recipients were
evaluated by staining with the GC markers GL7, CD38,
and PNA. Immune Tg B cells from the spleen of carrierprimed recipients profoundly expand, however, they fail
to express a GC phenotype (Figure 5b), whereas in noncarrier primed mice, Tg B cells do express GC markers
in the spleen (Figure 1b). In contrast to that observed in
the spleen, immune Tg B cells taken from LN of identical recipients fully differentiated into follicular GC B
cells (GL7+ CD38– PNA+). That is, in an individual
mouse, Tg B cells expanded in both the LN and spleen,
but in the spleen they diverted to an extrafollicular
pathway and in the LN to a follicular pathway. These
results were confirmed by examining the histology of
spleen and LN sections from carrier-primed recipients.
Similar to the histology of αCD40-treated mice (Figure
1d), extrafollicular localization of splenic Tg B cells was
observed (Figure 5c). In contrast, Tg B cells from the
LNs of the same primed recipients had entered follicles.
The observation that GC formation was selectively
overridden by carrier-primed Th cells in the spleen and
not the LN implied that long-lived plasma cells may
only be generated in the LN under these prescribed
conditions. To test this hypothesis, Tg B cells from
primed spleen and LN were passively transferred into
recipient mice, and the number of ASCs in the bone
marrow of recipient mice was determined. Tg B cells
from primed LN gave rise to higher numbers of bone
marrow plasma cells (Figure 5d). While we cannot
directly attribute these effects to heightened CD154
expression on Th cells, the data suggest that when the
immune response intensifies, the spleen assumes the
responsibility for the production of short-lived,
extrafollicular ASCs, while the LN continues to drive B
cells through a follicular GC-type response.

Discussion
The studies presented show that the differentiation
pathway of antigen-experienced B cells can be altered
by a CD40 agonist or the intensity of T cell help. We
demonstrate that the administration of a CD40 agonist induces extrafollicular B cell differentiation resulting in the loss in GC formation, a modest increase in
serum Ig levels, the premature termination of the
humoral immune response, the ablation of long-lived
bone marrow plasma cells, and the loss in the generation of B cell memory. The fate of antigen-reactive B
cells can also be altered by heightened T cell help, however, in a more restricted, organ-specific fashion.
There has been much interest as to the role of CD40 in
the terminal differentiation of B cells. The results presented herein lead to the conclusion that αCD40 adminThe Journal of Clinical Investigation
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istration in vivo directs extrafollicular B cell differentiation. However, in vitro studies of the role of CD40 agonists on the differentiation of B cells are conflicting. On
one hand, two published reports have shown that CD40
signaling in vitro can prevent B cell differentiation to
plasma cells (27, 28). Arpin et al. have shown that human
GC cells cultured with the cytokines IL-2 and IL-10 and
CD154-transfected cells acquire a memory B cell phenotype and that the withdrawal of CD154 resulted in terminal differentiation to ASCs (29). On the other hand, a
number of reports have shown CD40 signaling in vitro
directly induces B cell differentiation and Ab secretion
(30–32). First, in vivo and in vitro approaches are vastly
different, and second, the in vitro studies were performed in the absence of antigen. Our own studies show
that the impact of CD40 agonists are only observed in
the presence of antigen and preclude B cells from entering the follicular pathway.
In agreement with our data showing that heightened
levels of CD40 signaling promotes extrafollicular B cell
differentiation, a recent study by Uchida et al. has demonstrated that overexpression of a constitutive CD40-like
signaling molecule, LMP-1, promotes extrafollicular differentiation (33). Uchida and colleagues demonstrated
that antigenic challenge of LMP-1 Tg mice induced
extrafollicular B cell responses and failed to initiate GC
formation and the production of high-affinity Ab’s. As
with the αCD40 agonist, signaling through LMP-1
actively suppresses GC formation of differentiating B
cells and fosters extrafollicular differentiation. It is noteworthy that Epstein-Barr virus–transformed B cells
detected in lymphoid tissues of infectious mononucleosis patients are found neither in primary follicles nor
GCs, but in the extrafollicular areas (34, 35). All of these
data are in accord with the hypothesis that the triggering
of the CD40 signaling cascade by a CD40 agonist or
expression of LMP-1 diverts B cell differentiation.
One potential mechanism for the in vivo effects of
αCD40 mAb treatment on B cell differentiation is that
the mAb may interfere with B cell migration. Experimental data showing that GC responses were ablated
in the spleens of carrier-primed recipients suggest that
mAb treatment does not directly alter B cell migration.
Of interest is whether the differences in GC responses
between spleen and LN of hyperimmune mice are due
to differences in chemokine responsiveness. A recent
study by Hargreaves and coworkers demonstrated that
as splenic B cells differentiate into ASCs they undergo
changes in their ability to respond to chemokines (36).
Understanding the impact of CD40 agonists on B cell
differentiation in vivo both has practical advantages
and provides insights into the physiological function of
CD40 in terminal B cell differentiation. With regard to
the former, CD40 agonists have received attention as
potential adjuvants in vaccine development. The in vivo
use of agonistic αCD40 Ab’s has been shown previously to enhance isotype-switched Ab responses to TI antigens such as pneumococcal polysaccharides (3) and to
ameliorate collagen-induced arthritis with long-term
March 2002
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αCD40 treatment (37). However, our studies demonstrate that while αCD40 administration can transiently enhance antigen-specific Ig levels, it can also enforce
the premature termination of long-lived humoral
immunity and B cell memory. These findings raise
issues with the use of CD40 agonists for enhancing
long-term immunity. From a physiological standpoint,
these studies have uncovered a novel effect of CD40
agonism during a normal immune response. In a primary immune response, antigen-specific GC responses
were readily observed in both the spleen and LN. However, when the helper T cell compartment was hyperimmune, the response in the spleen was diverted to a nonGC, extrafollicular response, while the LN sustained a
GC reaction. More in-depth analysis showed that in a
carrier-primed mouse the Tg B cells from the LN, but
not the spleen, could develop into bone marrow plasma
cells. At this time, we cannot directly attribute the differential effects in the spleen versus LN to heightened
CD154 expression on the antigen-reactive Th cells, but
it is consistent with data presented using a CD40 agonist. More importantly, these studies suggest that as the
immune response matures and T cell help intensifies,
the function of the spleen and LN diverge, and each
assumes distinct responsibilities for sustaining the
humoral immune response. Late in an immune
response, we would hypothesize that the spleen acquires
the responsibility of producing short-lived ASCs, while
the LN produces memory B cells and long-lived ASCs
for export to the bone marrow. A more extensive testing
of this novel hypothesis is currently underway.
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